Physician

Amanda Melissa Gomes, M.D.

According to 2025 Medicare claims, Amanda Gomes, M.D. (NPI: 1649431321) practices nephrology in the Bay City, MI market, with the plurality of this provider's patient population coming from Bay, MI. This provider's primary affiliated billing organization is DIALYSIS AND NEPHROLOGY CONSULTANTS PC (NPI: 1104891159; TIN: 382385752) and primary practice location at 48708-6831. Gomes is affiliated with the POM ACO (ACO ID: A1297), McLaren High Performance Network, LLC (ACO ID: A3317), Mosaic ACO (ACO ID: A5033), and Aledade 155 National MSSP (ACO ID: A5358), participating under the MSSP model.

Gomes' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 567 traditional Medicare patients, billed 2,137 HCPCS/CPT codes, and received $203,623 in Medicare payments. The top billing code was 90961 (Dialysis services, 2-3 physician visits per month (20 years or older)). Part D data shows 1,163 prescription claims across 309 beneficiaries totaling $198,024 in drug costs, led by Jardiance (Empagliflozin). Open Payments data shows 2 records totaling $29. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $262,371 to $203,623. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $100,437 and ending at $198,024. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	932	3,473	$262,371
2016	909	3,281	$230,863
2017	829	3,165	$221,133
2018	783	2,692	$201,867
2019	706	2,685	$197,915
2020	605	2,222	$172,657
2021	558	1,991	$191,653
2022	489	1,614	$149,842
2023	493	1,783	$173,886
2024	567	2,137	$203,623

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	401	1,550	$100,437
2016	418	1,755	$172,765
2017	407	1,635	$135,463
2018	394	1,655	$98,889
2019	361	1,540	$89,792
2020	323	1,437	$56,667
2021	333	1,316	$68,820
2022	265	932	$84,648
2023	262	924	$115,532
2024	309	1,163	$198,024

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90961	Dialysis services, 2-3 physician visits per month (20 years or older)	48	210	$247
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	156	178	$139
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	52	78	$106
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	209	994	$64
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	280	446	$57

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	64	4,020	$74,420
Lokelma	Sodium Zirconium Cyclosilicate	21	1,017	$20,847
Veltassa	Patiromer Calcium Sorbitex	19	664	$18,516
Farxiga	Dapagliflozin Propanediol	20	970	$17,928
Sevelamer Carbonate	Sevelamer Carbonate	42	2,528	$9,014

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$29	Bayer Healthcare Pharmaceuticals Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Amanda Melissa Gomes, M.D.?

Tedicare shows public-source Medicare data for Amanda Melissa Gomes, M.D. (NPI 1649431321), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Amanda Melissa Gomes, M.D. have ACO affiliation data?

Amanda Melissa Gomes, M.D. is shown with ACO affiliation data for POM ACO (MSSP, ACO ID A1297), McLaren High Performance Network, LLC (MSSP, ACO ID A3317), Mosaic ACO (MSSP, ACO ID A5033), and Aledade 155 National MSSP (MSSP, ACO ID A5358).

What billing organization is linked to Amanda Melissa Gomes, M.D.?

Amanda Melissa Gomes, M.D. is linked to DIALYSIS AND NEPHROLOGY CONSULTANTS PC (billing NPI 1104891159) in the available physician profile data.

Does Amanda Melissa Gomes, M.D. have Open Payments data?

Amanda Melissa Gomes, M.D. has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.